News Releases

Sep. 18, 2003

New Oita Plant Facilities for Bulk Pharmaceuticals Production and Meropen® Formulation Completed

Sumitomo Chemical Co., Ltd. and Sumitomo Pharmaceuticals Co., Ltd., announced today that new facilities have been completed in Oita, Japan for bulk pharmaceuticals production and Meropen® formulation, representing a total capital expenditure of approximately 10 billion yen.

In anticipation of increased bulk production to meet the growth in pharmaceutical sales and increasingly stringent GMP (Good Manufacturing Practice) standards worldwide, the two companies have expedited joint efforts to further enhance pharmaceutical production in Oita. For one thing, the existing bulk pharmaceuticals production unit at Sumitomo Chemicalfs Oita Works was turned over to the exclusive bulk manufacture of the carbapenem antibiotic hMeropen®.h New facilities for production of other bulk pharmaceuticals were also constructed. In addition, the new Meropen® formulation facility was located next to the site for Meropen® bulk production.

Construction of the new facilities began in August 2002, and was completed on September 18, 2003 as scheduled. Following a series of validations* and test runs, the facilities will go into full operation in the autumn of 2004.

The new bulk pharmaceuticals production facility is a five-story multiple product-line plant designed for maximum efficiency from reception of raw materials to production, storage and shipment of bulk pharmaceuticals.
The new two-story Meropen® formulation facility, geared for production and quality assurance, is equipped with rooms for mixing, filling and packaging as well as testing laboratories.

Sumitomo Pharmaceuticals took over the production of bulk pharmaceuticals from Sumitomo Chemical in April of this year, establishing these operations at its Production Divisionfs Oita Plant, which will oversee the new facilities for bulk pharmaceuticals production and Meropen® formulation. Sumitomo Pharmaceuticals is firmly committed to fortifying its production and quality assuarance under its strategy of fully integrated production from bulk pharmaceuticals to formulation, in order to further increase production efficiency and strengthen its competitiveness.

* Documentation confirming that the structure, equipment, procedures, processes and other production and quality assurance methods of a manufacturing facility produce the expected results (as defined by GMP)

Overview of the new production facility for bulk pharmaceuticals

Address : 2200, Tsurusaki, Oita, 870-0106
Structure : Steel-frame, five stories above ground
Building area : 1,758 square meter
Total floor area : 4,814 square meter
Construction begun : August 2, 2002
Completed : September 18, 2003

image

Overview of the new Meropen® formulation facility

Address : 2200, Tsurusaki, Oita, 870-0106
Structure : Steel-frame, two stories above ground
Building area : 4,108 square meter
Total floor area : 6,908 square meter
Construction begun : September 10, 2002
Completed : September 18, 2003

image